ERK2-regulated TIMP1 induces hyperproliferation of K-RasG12D-transformed pancreatic ductal cells

Neoplasia (United States)

Volumn 15, Issue 4, 2013, Pages 359-372

  Botta, Gregory P ^a,b   Reichert, Maximilian ^b   Reginato, Mauricio J ^a   Heeg, Steffen ^b,c   Rustgi, Anil K ^b   Lelkes, Peter I ^d  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTEGRIN; ALPHA3 INTEGRIN; ALPHA6 INTEGRIN; BETA6 INTEGRIN; COLLAGENASE 3; CONNECTIVE TISSUE GROWTH FACTOR; GREEN FLUORESCENT PROTEIN; INTERSTITIAL COLLAGENASE; K RAS PROTEIN; MACROPHAGE ELASTASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P53; STROMELYSIN 2; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL ISOLATION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84875653169     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121708     Document Type: Article

References (58)

1. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, and DePinho RA (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20, 1218-1249.
2. Reichert M and Rustgi A (2011). Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest 121, 4572-4578.
3. Chu GC, Kimmelman AC, Hezel AF, and DePinho RA (2007). Stromal biology of pancreatic cancer. J Cell Biochem 101, 887-907.
4. Deramaudt T and Rustgi AK (2005). Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 1756, 97-101.
5. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, et al. (2003). Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63, 8614-8622.
6. Drosten M, Dhawahir A, Sum EYM, Urosevic J, Lechuga CG, Esteban LM, Castellano E, Guerra C, Santos E, and Barbacid M (2010). Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J 29, 1091-1104.
7. Botta GP, Reginato MJ, Reichert M, Rustgi AK, and Lelkes PI (2012). Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1. Mol Cancer Res 10, 183-196.
8. Jiang Y, Goldberg ID, and Shi YE (2002). Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21, 2245-2252.
9. Bramhall SR, Neoptolemos JP, Stamp GW, and Lemoine NR (1997). Imbalance ofexpression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 182, 347-355.
10. Bloomston M, Shafii A, Zervos EE, Rojiani A, and Rosemurgy AS (2002). MMP-2 and TIMP-1 are derived from, not in response to, pancreatic cancer. J Surg Res 102, 35-38.
11. Bourboulia D and Stetler-Stevenson WG (2010). Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20, 161-168.
12. Dean G, Young DA, Edwards DR, and Clark IM (2000). The human tissue inhibitor of metalloproteinases (TIMP)-1 gene contains repressive elements within the promoter and intron 1. J Biol Chem 275, 32664-32671.
13. Fata JE, Leco KJ, Moorehead RA, Martin DC, and Khokha R (1999). Timp-1 is important for epithelial proliferation and branching morphogenesis during mouse mammary development. Dev Biol 211, 238-254.
14. Hall M-C, Young DA, Waters JG, Rowan AD, Chantry A, Edwards DR, and Clark IM (2003). The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-β1. J Biol Chem 278, 10304-10313.
15. Bramhall SR, Stamp GW, Dunn J, Lemoine NR, and Neoptolemos JP (1996). Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 73, 972-978.
16. Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, Mavrommatis J, Katsarou S, and Davaris P (2002). Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 197, 307-313.
17. Bloomston M, Shafii A, Zervos EE, and Rosemurgy AS (2002). TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res 102, 39-44.
18. Bigelow RLH, Williams BJ, Carroll JL, Daves LK, and Cardelli JA (2009). TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro. Breast Cancer Res Treat 117, 31-44.
19. Rossi L, Ergen AV, and Goodell MA (2011). TIMP-1 deficiency subverts cellcycle dynamics in murine long-term HSCs. Blood 117, 6479-6488.
20. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, and Iwata K (1992). Growthpromoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298, 29-32.
21. Ritter LM, Garfield SH, and Thorgeirsson UP (1999). Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells. Biochem Biophys Res Commun 257, 494-499.
22. Davidsen ML, Würtz S, Rømer MU, Sørensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brünner N, and Lademann U (2006). TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 95, 1114-1120.
23. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, and Der CJ (2007). K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 67, 2098-2106.
24. Schreiber FS, Deramaudt TB, Brunner TB, Boretti MI, Gooch KJ, Stoffers DA, Bernhard EJ, and Rustgi AK (2004). Successful growth and characterization of mouse pancreatic ductal cells: functional properties of the Ki-RAS(G12V) oncogene. Gastroenterology 127, 250-260.
25. Reichert M, Takano S, Von Burstin J, Kim S-B, Lee J-S, Ihida-Stansbury K, Hahn C, Heeg S, Schneider G, Rhim AD, et al. (2013). The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis. Genes Dev 27, 288-300.
26. Gu G, Dubauskaite J, and Melton DA (2002). Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129, 2447-2457.
27. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, and Tuveson DA (2001). Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15, 3243-3248.
28. Chen F, Hancock C, Macias A, Joh J, Still K, Zhong S, Mackerell AD, and Shapiro P (2007). Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. J Biol Chem16, 6281-6287.
29. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, et al. (2008). Mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5, e123.
30. Mahadevan D and Von Hoff DD (2007). Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6, 1186-1197.
31. Edwards DR, Rocheleau H, Sharma RR, Wills AJ, Cowie A, Hassell JA, and Heath JK (1992). Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription. Biochim Biophys Acta 1171, 41-55.
32. Porter JF, Shen S, and DenhardtDT(2004). Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase. Br J Cancer 90, 463-470.
33. Howlin J, McBryan J, and Martin F (2006). Pubertal mammary gland development: insights frommouse models. J Mammary Gland Biol Neoplasia 11, 283-297.
34. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al. (2012). EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361.
35. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, and DePinho RA (2003). Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17, 3112-3126.
36. Shama J, Garcia-Medina R, Pouysségur J, and Vial E (2008). Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells. Biochem Biophys Res Commun 372, 845-849.
37. Lefloch R, Pouysségur J, and Lenormand P (2008). Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol 28, 511-527.
38. Vantaggiato C, Formentini I, Bondanza A, Naldini L, Brambilla R, and Bonini C (2006). ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol 5, 14.
39. Shin S, Dimitri CA, Yoon S-O, Dowdle W, and Blenis J (2010). ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 38, 114-127.
40. Botta GP, Manley P, Miller S, and Lelkes PI (2006). Real-time assessment of three-dimensional cell aggregation in rotating wall vessel bioreactors in vitro. Nat Protoc 1, 2116-2127.
41. Liu X-W, Bernardo MM, Fridman R, and Kim H-RC (2003). Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 278, 40364-40372.
42. Giehl K, Skripczynski B, Mansard A, Menke A, and Gierschik P (2000). Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene 19, 2930-2942.
43. Skarpen E, Flinder LI, Rosseland CM, Orstavik S, Wierød L, Oksvold MP, Skålhegg BS, and HuitfeldtHS (2008). MEK1 and MEK2regulate distinct functions by sorting ERK2 to different intracellular compartments. FASEB J 22, 466-476.
44. Ring AY, Sours KM, Lee T, and Ahn NG (2012). Distinct patterns of activationdependent changes in conformational mobility between ERK1 and ERK2. Int J Mass Spectrom 302, 101-109.
45. Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl CD, Johnstone CN, Klein-Szanto AJ, El-Deiry WS, Cukierman E, et al. (2007). The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev 21, 2788-2803.
46. Poulikakos PI, Zhang C, Bollag G, Shokat KM, and Rosen N (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430.
47. Pan S, Chen R, Crispin DA, May D, Stevens T, Mcintosh M, Bronner MP, Ziogas A, Anton-Culver H, and Brentnall TA (2011). Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J Proteome Res 10, 2359-2376.
48. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, et al. (2011). Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 17, 805-816.
49. Chakrabarti O, Veeraraghavalu K, Tergaonkar V, Liu Y, Androphy EJ, Stanley MA, and Krishna S (2004). Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J Virol 78, 5934-5945.
50. Mohammed FF, Pennington CJ, Kassiri Z, Rubin JS, Soloway PD, Ruther U, Edwards DR, and Khokha R (2005). Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology 41, 857-867.
51. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, Jurkowska G, and Szmitkowski M (2009). Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 38, 613-618.
52. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, et al. (2011). Mechanistic rationale for inhibition of poly(ADPribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664-678.
53. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, and Winberg J-O (2011). Regulation of matrix metalloproteinase activity in health and disease. FEBS J 278, 28-45.
54. EgebladMand Werb Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2, 161-174.
55. Jung K-K, Liu X-W, Chirco R, Fridman R, and Kim H-RC (2006). Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 25, 3934-3942.
56. Pasca di Magliano M, Biankin AV, Heiser PW, Cano DA, Gutierrez PJA, Deramaudt T, Segara D, Dawson AC, Kench JG, Henshall SM, et al. (2007). Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PloS One 2, e1155.
57. Heiser P, Cano D, Landsman L, and Kim G (2008). Stabilization of β-catenin induces pancreas tumor formation. Gastroenterology 135, 1288-1300.
58. Rigg AS and Lemoine NR (2001). Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Ther 8, 869-878.